MA-SIGNIANT
Signiant, the market leader in intelligent file movement software, today announced that Smoke & Mirrors , a leading visual effects and post production company, is utilizing Signiant’s Media Shuttle ™ hybrid SaaS file transfer solution to move large media files quickly, efficiently and securely among more than 1,000 customer, partner and internal users.
Using the Signiant platform, Smoke & Mirrors now moves large files several times faster than it did before when using FTP technologies. The speed and reliability of the Signiant transfers has also enabled the company to cut back on shipping content physically on CDs and media drives and establish more streamlined, efficient workflows, according to Adam Jakubowski, technical operations manager at Smoke & Mirrors.
“Media Shuttle has helped us be more flexible in our own processes – to work much quicker to meet clients’ deadlines and avoid situations where content may not reach its destination at all,” Jakubowski said. “Whenever we talk with people on the frontlines – customers, partners and our own staff – there’s always more of a comfort level now that we’re sending media files over Media Shuttle. Plus, it’s given us more visibility into the volumes of content that are moving through the system.”
Smoke & Mirrors now moves most of its media files using Media Shuttle, sharing content with media professionals who need to review content in various stages of development. File sizes moved over the system range from just a few MB for small audio files to more than 100 GB for larger, extended rich media content.
“We’re actually encouraging users to use Media Shuttle for everything – smaller files all the way up to full TV commercial campaigns – because it’s so efficient,” Jakubowski said.
In the first seven months of active usage, Smoke & Mirrors moved more than 30 TB of content, averaging nearly 1,000 transfers a month and 5 GB per transmission.
“Having access to Media Shuttle has helped Smoke & Mirrors meet a number of deadlines and accelerate the pace of certain projects at strategic times,” Jakubowski said. On one job, a creative agency partner in New York projected that it would take a 280 GB batch of content 24 hours to arrive at the Smoke & Mirrors Shanghai office via FTP. Smoke & Mirrors equipped the partner with a Media Shuttle portal, and the same content moved in a third of the time.
“Smoke & Mirrors provides a perfect example for how Signiant Media Shuttle’s fast, reliable and secure technologies can drive significant improvements in various media workflows,” said Margaret Craig, CEO at Signiant. “We’re thrilled with the results Smoke & Mirrors has been able to achieve, and we look forward to continuing to help them and others in the industry improve efficiency and accomplish their business goals.”
To learn more about Signiant’s Media Shuttle and its work with Smoke & Mirrors, visit Signiant at IBC at Booth No. 14.L08.
About Signiant
Signiant’s intelligent file movement software helps the world’s top content creators and distributors ensure fast, secure delivery of large files over public and private networks. Built on Signiant’s patented technology, the company’s on-premises software and SaaS solutions move petabytes of high-value data every day between users, applications and systems with proven ease. www.signiant.com
About Smoke & Mirrors
Smoke & Mirrors is a highly creative and dedicated visual effects and full service post production company, providing international excellence, innovation and expertise for the advertising, film and music industries. Established in 1995 as the original post boutique, Smoke & Mirrors has since consistently delivered exciting, visually stimulating and contemporary work. www.smoke-mirrors.com
Contact:
Media Contacts:
Signiant
Katie Staveley, +1 781 221 4030
VP
of Marketing
kstaveley@signiant.com
or
PAN
Communications
Ariel Burch, +1 617-502-4300
Signiant@pancomm.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum